The Trump administration is reportedly drafting a plan that would allow temporary peptide compounding sales, according to The Washington Post. However, nothing has been announced. The report rests on two people familiar with the matter, who spoke anonymously.
What the Report Says About Peptide Compounding
The Post reports that officials are crafting plans to allow the temporary sale of certain previously restricted peptides. Federal health officials are still working out new regulations for the products. In the meantime, some compounding pharmacies could dispense them.
That includes peptides marketed as new medical treatments and wellness products. Because the claims about what they treat have not been fully safety tested, the Post notes the risk, as Political Wire’s summary of the story shows.
We found no official HHS or FDA notice confirming any of this. So far, the mechanism, the timing, and the exact list of peptides are not publicly confirmed. Treat the details as early and subject to change. For wider context on the policy shift, see our earlier look at how the FDA may ease peptide restrictions.
How We Got Here: The Road to Compounded Peptides
This did not come out of nowhere. HHS Secretary Robert F. Kennedy Jr. said on Joe Rogan’s podcast in February that about 14 peptides would become more accessible. He has called the earlier restrictions a “war on peptides.”
Back in 2023, FDA placed 19 peptides on a list of substances with significant safety risks. Later, the agency said it would pull 12 of them from that list after nominators withdrew their requests, according to law firm Orrick. However, removal alone does not authorize compounding.
The Advisory Panel Vote
In late July, FDA’s compounding advisory committee narrowly backed six of seven peptides for the 503A bulks list. Those are BPC-157, KPV, TB-500, MOTS-c, Semax, and epitalon. The panel rejected emideltide. Notably, BPC-157, KPV, and TB-500 each passed 8-6 with one abstention, AJMC reports.
Those votes are non-binding. FDA still has to sign off, and legal compounding still requires formal rulemaking. Also, none of these substances is FDA-approved, so any peptide sales would involve unapproved peptides.
Why Critics Question Unapproved Peptides
FDA’s own staff had recommended against all seven peptides. Their briefing materials called the studies, including five BPC-157 trials, too short and too small to establish safety or effectiveness.
There is also a conflict-of-interest debate. UC Davis cell biologist Paul Knoepfler has questioned the panel’s makeup, and Pharmaceutical Executive reports that some appointees have ties to peptide-providing clinics. An HHS spokesperson said all members went through the same ethics review required of every FDA advisory committee member, per the same outlet.
What to Watch Next
The first thing to watch is whether HHS or FDA formally announces anything. If the report is accurate, a notice or an enforcement-discretion statement would be the sign. Beyond that, the formal path still runs through FDA acceptance and notice-and-comment rulemaking. That process commonly takes 8 to 12 months. A further advisory meeting on additional peptides is also expected before the end of February 2027.
Meanwhile, many of these peptides already sell on grey and black markets with little human trial data behind them. Our piece on how science, regulation, and trust are reshaping the peptide boom explains why that matters. If you take or are considering one, talk to your doctor first. A temporary sales window would not make the products tested, and peptide compounding under any new rule would still carry the same open safety questions.
